Skip to content

Fast Facts

Company Overview

Founded in 1950, Allergan, Inc., with headquarters in Irvine, California, is a multi-specialty health care company that discovers, develops and commercializes innovative pharmaceuticals, biologics and medical devices that enable people to live life to its greatest potential — to see more clearly, move more freely, express themselves more fully. The Company employs more than 8,000 people worldwide and operates state-of-the-art R&D facilities and world-class manufacturing plants. In addition to its discovery-to-development research organization, Allergan has global marketing and sales capabilities with a presence in more than 100 countries.

Number of Employees

Allergan employs more than 8,000 people worldwide and operates world-class research and development facilities and state-of-the-art manufacturing plants. In addition to its discovery-to-development research programs, Allergan has global marketing and sales capabilities, with a presence in more than 100 countries.

Year Founded

1950

Corporate Headquarters

Irvine, California

Chief Executive Officer and Chairman of the Board

David E. I. Pyott

Executive Committee

David E. I. Pyott
F. Michael Ball
Raymond H. Diradoorian
Dianne Dyer-Bruggeman
Jeffrey L. Edwards
Douglas S. Ingram, J.D.
Scott M. Whitcup, M.D.

Key Financials

For the quarter ended September 30, 2009

  • Allergan's total product net sales were $1,127.8 million. Total product net sales increased 4.2 percent as compared to total product net sales in the third quarter of 2008. On a constant currency basis, total product net sales increased 7.0 percent compared to total product net sales in the third quarter of 2008.
  • Total specialty pharmaceuticals net sales increased 7.8 percent as compared to total specialty pharmaceuticals net sales in the third quarter of 2008. On a constant currency basis, total specialty pharmaceuticals net sales increased 10.7 percent compared to total specialty pharmaceuticals net sales in the third quarter of 2008.
  • Total medical devices net sales decreased 10.6 percent, or 8.3 percent on a constant currency basis, compared to total medical devices net sales in the third quarter of 2008.

For the quarter ended June 30, 2009

  • Allergan's total product net sales were $1,118.7 million. Total product net sales decreased 3.2 percent as compared to total product net sales in the second quarter of 2008. On a constant currency basis, total product net sales increased 2.2 percent compared to total product net sales in the second quarter of 2008.
  • Total specialty pharmaceuticals net sales decreased 0.6 percent as compared to total specialty pharmaceuticals net sales in the second quarter of 2008. On a constant currency basis, total specialty pharmaceuticals net sales increased 4.8 percent compared to total specialty pharmaceuticals net sales in the second quarter of 2008.
  • Total medical devices net sales decreased 13.9 percent, or 8.5 percent on a constant currency basis, compared to total medical devices net sales in the second quarter of 2008.

For the quarter ended March 31, 2009

  • Allergan's total product net sales were $994.6 million. Total product net sales decreased 6.3 percent as compared to total product net sales in the first quarter of 2008. On a constant currency basis, total product net sales decreased 0.4 percent compared to total product net sales in the first quarter of 2008.
  • Total specialty pharmaceuticals net sales decreased 3.6 percent as compared to total specialty pharmaceuticals net sales in the first quarter of 2008. On a constant currency basis, total specialty pharmaceuticals net sales increased 2.3 percent compared to total specialty pharmaceuticals net sales in the first quarter of 2008.
  • Total medical devices net sales decreased 17.6 percent, or 11.6 percent at constant currency, compared to total medical devices net sales in the first quarter of 2008.

2008

  • For the year ending 2008, total product net sales totaled $4.3 billion, a 12 percent increase over 2007.
  • Total BOTOX® sales were $1.3 billion in 2008, an increase of 8 percent over 2007. For full year 2008, therapeutic sales accounted for approximately 50 percent of total BOTOX® sales and cosmetic sales accounted for approximately 50 percent of total BOTOX® sales.
  • LUMIGAN® franchise sales were $426 million in 2008, an increase of 9 percent over 2007.
  • Sales of RESTASIS® were $444 million in 2008, an increase of 29 percent over 2007.

Allergan Research and Development

  • Allergan increased R&D spending 13 percent in 2008 over 2007, to approximately $729 million.1
  • Allergan ranks in the top quartile of its peer group companies for R&D investment as a percentage of sales in both the pharmaceutical and medical device industries.2

Acquisitions

Esprit Pharma Holding Company, Inc.
In October 2007, Allergan acquired Esprit Pharma, Inc. Upon completion of the acquisition Allergan obtained U.S. marketing rights to SANCTURA®, a twice-a-day anthicholinergic approved for the treatment of overactive bladder (OAB), and SANCTURA XR™, a once-daily formulation of SANCTURA®, which has shown to be effective while significantly reducing typical side effects such as dry mouth associated with many OAB medications. Allergan's acquisition of Esprit aligns with Allergan's strategic interest in the urologics market.

EndoArt SA
In February 2007, Allergan announced completion of its acquisition of EndoArt. The acquisition gained Allergan ownership of EndoArt's proprietary technology platform, including FLOWATCH® technology, which powers the EASYBAND® Remote Adjustable Gastric Band System, a next-generation, telemetrically adjustable gastric banding device for the treatment of morbid obesity.

Groupe Corneal Laboratoires
In January 2007, Allergan completed the acquisition of Groupe Corneal Laboratoires, obtaining exclusive rights to market and manufacture the JUVEDÉRM™ dermal filler family of products.

Inamed Corporation
In March 2006, Allergan acquired Inamed Corporation. The acquisition of Inamed expanded Allergan's global position as a premier biomedical company in high-growth markets and created a world-leading medical aesthetics franchise, providing a broad, complementary portfolio of pharmaceutical and medical device products to physicians and patients.



  1. Adjustments to GAAP research and development expense used to calculate research and development expense, adjusted for non-GAAP items, include the following: $68.7 million for upfront payments for technologies, that have not achieved regulatory approval and $0.3 million of termination benefits related to the phased closure of the Arklow, Ireland, breast implant manufacturing plant in 2008; $72.0 million of in-process research and development expense related to the EndoArt acquisition in 2007; $579.3 million of in-process research and development expense related to the Inamed acquisition, $0.2 million of Inamed integration and transition costs and $0.5 million of transition/duplicate operating expenses in 2006; and $1.5 million of transition/duplicate operating expenses and a $3.0 million buy-out of a license agreement in 2005. GAAP research and development expense was $797.9 million, $718.1 million, $1,055.5 million, $388.3 million, and $342.9 million in 2008, 2007, 2006, 2005 and 2004, respectively. GAAP research and development expense growth (decline) was 11%, (32%), 172%, 13% and (55%) for 2008, 2007, 2006, 2005 and 2004, respectively.
  2. Internal analysis of public filing of Allergan peer group.